“Bluebird’s stock falls 21% as it says it will focus on U.S. market for gene therapies, citing ‘European payers'”
August 9, 2021
“Shares of Bluebird Bio Inc. were down 21.6% in premarket trading on Monday after the company announced several setbacks to its business as part of its second-quarter earnings announcement. Bluebird plans to wind down its gene therapy operations in Europe, citing “European payers,” which are primarily governments there. “European payers have not yet evolved their approach to gene therapy in a way that can recognize the innovation and the expected life-long benefit of these products,”…”
https://finance.yahoo.com/m/78ccd271-2405-359c-bef6-049bda63921a/bluebird-s-stock-falls-21-as.html